Ligand Pharmaceuticals Inc
SWB:LGDN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Ligand Pharmaceuticals Inc
SWB:LGDN
|
US |
|
S
|
Seelos Therapeutics Inc
XBER:NXEN
|
US |
|
M
|
MGM Resorts International
DUS:MGG
|
US |
|
T
|
TravelSky Technology Ltd
OTC:TSYHF
|
CN |
|
H
|
Helmerich and Payne Inc
LSE:0J4G
|
US |
|
T
|
Tsingtao Brewery Co Ltd
SWB:TSI
|
CN |
|
Markel Corp
NYSE:MKL
|
US |
|
M
|
Marsh & McLennan Companies Inc
XMUN:MSN
|
US |
|
Dave Inc
NASDAQ:DAVE
|
US |
|
G
|
G2 Energy Corp
CNSX:GTOO
|
CA |
|
B
|
Buckle Inc
SWB:BK2
|
US |
|
I
|
ITV PLC
OTC:ITVPF
|
UK |
|
Barsele Minerals Corp
F:HEG
|
CA |
Wall St Price Targets
LGDN Price Targets Summary
Ligand Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for LGDN is 204.98 EUR with a low forecast of 182.18 EUR and a high forecast of 238.47 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LGDN's stock price target?
Price Target
204.98
EUR
According to Wall Street analysts, the average 1-year price target for LGDN is 204.98 EUR with a low forecast of 182.18 EUR and a high forecast of 238.47 EUR.
What is the Revenue forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
13%
Over the last 14 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 13%.
What is the Operating Income forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
29%
Over the last 14 years, the compound annual growth rate for Operating Income has been 26%. The projected CAGR for the next 8 years is 29%.
What is the Net Income forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 14 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 7 years is 17%.
